Literature DB >> 1824934

Mapping of the high affinity Fc epsilon receptor binding site to the third constant region domain of IgE.

A Nissim1, M H Jouvin, Z Eshhar.   

Abstract

Identification of the precise region(s) on the IgE molecule that take part in the binding of IgE to its high affinity receptor (Fc epsilon RI) may lead to the design of IgE analogues able to block the allergic response. To localize the Fc epsilon RI-binding domain of mouse IgE, we attempted to confer on human IgE, which normally does not bind to the rodent receptor, the ability to bind to the rat Fc epsilon RI. Employing exon shuffling, we have expressed chimeric epsilon-heavy chain genes composed of a mouse (4-hydroxy-3-nitrophenyl)acetic acid (NP)-binding VH domain, and human C epsilon in which various domains were replaced by their murine counterparts. This has enabled us to test the Fc epsilon RI-binding of each mouse IgE domain while maintaining the overall conformation of the molecule. All of the chimeric IgE molecules which contain the murine C epsilon 3, bound equally to both the rodent and human receptor, as well as to monoclonal antibodies recognizing a site on IgE which is identical or very close to the Fc epsilon RI binding site. Deletion of the second constant region domain did not impair either the binding capacity of the mutated IgE or its ability to mediate mast cell degradation. These results assign the third epsilon domain of IgE as the principal region involved in the interaction with the Fc epsilon RI.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824934      PMCID: PMC452617          DOI: 10.1002/j.1460-2075.1991.tb07925.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  34 in total

Review 1.  Structure-function relationships in human immunoglobulin E.

Authors:  K J Dorrington; H H Bennich
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

2.  Thermally induced structural changes in immunoglobulin E.

Authors:  K J Dorrington; H Bennich
Journal:  J Biol Chem       Date:  1973-12-25       Impact factor: 5.157

3.  Inhibition of Prausnitz-Küstner reaction by proteolytic-cleavage fragments of a human myeloma protein of immunoglobulin class E.

Authors:  D R Stanworth; J H Humphrey; H Bennich; S G Johansson
Journal:  Lancet       Date:  1968-07-06       Impact factor: 79.321

4.  Failure of the putative IgE pentapeptide to compete with IgE for receptors on basophils and masts cells.

Authors:  H Bennich; U Ragnarsson; S G Johansson; K Ishizaka; T Ishizaka; D A Levy; L M Lichtenstein
Journal:  Int Arch Allergy Appl Immunol       Date:  1977

5.  Cloning of human immunoglobulin epsilon chain genes: evidence for multiple C epsilon genes.

Authors:  Y Nishida; T Miki; H Hisajima; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

6.  Cloning and nucleotide sequence of mouse immunoglobulin epsilon chain cDNA.

Authors:  F T Liu; K Albrandt; J G Sutcliffe; D H Katz
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

7.  Biologic function of the Fc fragments of E myeloma protein.

Authors:  K Ishizaka; T Ishizaka; E H Lee
Journal:  Immunochemistry       Date:  1970-08

8.  Generation of hybridomas secreting murine reaginic antibodies of anti-DNP specificity.

Authors:  Z Eshhar; M Ofarim; T Waks
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

9.  Biology of immunoglobulin E. Molecular basis of reaginic hypersensitivity.

Authors:  T Ishizaka; K Ishizaka
Journal:  Prog Allergy       Date:  1975

10.  Immunoglobulin gene expression in transformed lymphoid cells.

Authors:  V T Oi; S L Morrison; L A Herzenberg; P Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

View more
  1 in total

1.  Characterization of a second secreted IgE isoform and identification of an asymmetric pathway of IgE assembly.

Authors:  F D Batista; D G Efremov; O R Burrone
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.